安络化纤丸辅助治疗对乙肝肝硬化代偿期患者抗肝纤维化的影响

摘要/Abstract

摘要： 目的探讨安络化纤丸辅助治疗对乙肝肝硬化代偿期患者抗肝纤维化的影响。方法选择2020年5月—2022年5月聊城市传染病医院收治的106例乙肝肝硬化代偿期患者为研究对象,根据随机抽签法分为对照组与研究组,各53例。对照组患者给予替诺福韦治疗,研究组患者在对照组基础上联合口服安络化纤丸进行辅助治疗,连续治疗1年后比较两组治疗效果、抗肝纤维化指标[透明质酸（HA）、层黏蛋白（LN）、Ⅲ型前胶原肽（PⅢP）、Ⅳ型胶原蛋白（Ⅳ-C）]水平、肝功能指标[丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、总胆红素（TB）]水平、病毒[乙肝病毒核酸（HBV-DNA）]载量、炎症细胞因子[白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、超敏C反应蛋白（Hs-CRP）]水平、肝脏硬度及用药安全性。结果研究组患者治疗总有效率较对照组高,差异有统计学意义（P<0.05）。治疗前,两组患者肝纤维化各指标水平比较,差异无统计学意义（P>0.05）;治疗后,研究组患者HA、LN、PⅢP、Ⅳ-C水平均低于对照组,差异有统计学意义（P<0.05）。治疗前,两组患者ALT、AST、TB与HBV-DNA载量水平比较,差异无统计学意义（P>0.05）;治疗后,研究组患者ALT、AST、TB与HBV-DNA载量水平均低于对照组,差异有统计学意义（P<0.05）。治疗前,两组患者IL-6、TNF-α、Hs-CRP水平及肝脏硬度比较,差异无统计学意义（P>0.05）;治疗后,研究组患者IL-6、TNF-α、Hs-CRP水平及肝脏硬度均低于对照组,差异有统计学意义（P<0.05）。两组患者不良反应发生率比较,差异无统计学意义（P>0.05）,且两组均未发生严重不良反应。结论安络化纤丸辅助治疗可有效提升抗肝纤维化及抗病毒效果,抑制炎症反应,且安全性较高,值得临床应用。

关键词: 安络化纤丸, 乙肝肝硬化代偿期, 肝纤维化, 炎症反应, 肝功能, HBV-DNA载量

Abstract: Objective To investigate the effect of adjuvant therapy with Anluo HuaXian Wan on anti-liver fibrosis in patients with compensated hepatitis B cirrhosis. Methods A total of 106 patients with compensated hepatitis B cirrhosis in the Department of Gastroenterology and Hepatology of Liaocheng Infectious Disease Hospital from May 2020 to May 2022 were selected for the study, the enrolled patients were divided into control group and study group according to random drawing method, 53 cases in each group. Patients in the control group were treated with tenofovir, while patients in the study group were treated with oral Anluo HuaXian Wan as adjuvant therapy. The anti-fibrotic effect, liver function, viral load, levels of various inflammatory cytokines and liver stiffness, and the safety of the drug were evaluated in both groups after 1 year of continuous treatment. Results The total effective rate of treatment was higher in the study group than in the control group, with significant differences compared between groups (P<0.05). There was no difference in the levels of liver fibrosis indexes compared between the two groups of patients before treatment (P>0.05), and the levels of liver fibrosis indexes in the study group were lower than those in the control group after treatment (P<0.05). There was no difference between the liver function indexes and HBV-DNA load levels of patients in the two groups before treatment compared with each other (P>0.05), and the liver function indexes and HBV-DNA load levels of patients in the study group were lower than those of the control group after treatment (P<0.05). There was no difference in the levels of each inflammatory cytokine and liver hardness compared between the two groups before treatment (P>0.05), and the levels of each inflammatory cytokine and liver hardness of patients in the study group were lower than those in the control group after treatment (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05), and no serious adverse reactions occurred in either group. Conclusion The adjuvant therapy of Anluo HuaXian Wan can effectively enhance the anti-liver fibrosis and anti-viral effects, inhibit the inflammatory response, and has a high safety profile, which is worthy of clinical application.

Key words: Anluo Huaxian Wan, compensated hepatitis B cirrhosis, liver fibrosis, inflammatory response, liver function, HBV-DNA load

中图分类号:

R575

李玲玲, 王肖, 刘英果. 安络化纤丸辅助治疗对乙肝肝硬化代偿期患者抗肝纤维化的影响[J]. 中华养生保健, 2024, 42(5): 33-36.

LI Ling-ling, WANG Xiao, LIU Ying-guo. Effect of Adjuvant Therapy with Anluo Huaxian Wan on Anti-Liver Fibrosis in Patients with Compensated Hepatitis B Cirrhosis[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(5): 33-36.

参考文献

[1] 李宝华,何聪.安络化纤丸联合恩替卡韦治疗乙型肝炎肝硬化的临床疗效及作用机制[J].中药材,2022,45(10):2512-2515.
[2] 张莹雪,孙凤霞,李晓玲.安络化纤丸联合恩替卡韦治疗乙型肝炎肝硬化的系统评价[J].中国医院用药评价与分析,2022,22(1):70-76,82.
[3] 郭香娟,王敏,张洪涛,等.水飞蓟素胶囊联合替诺福韦对失代偿期乙肝肝硬化患者肝肾功能、肝纤维化及氧化应激水平的影响[J].疑难病杂志,2020,19(10):980-984.
[4] 甘雪梅,刘洪,左永清,等.替诺福韦联合安络化纤丸治疗乙肝肝硬化代偿期的疗效[J].西北药学杂志,2022,37(3):161-165.
[5] 徐小元,丁惠国,李文刚,等.肝硬化诊治指南[J].实用肝脏病杂志,2019,22(6):770-786.
[6] 中华中医药学会肝胆病专业委员会,中国民族医药学会肝病专业委员会,王灵台等.慢性乙型肝炎中医诊疗指南(2018年版)[J].中西医结合肝病杂志,2019,29(1):97-102.
[7] 张先,陈海燕.安络化纤丸联合恩替卡韦分散片治疗乙肝肝硬化的临床疗效研究[J].临床研究,2021,29(6):114-115.
[8] 赵巍峰,王园园,李赢,等.安络化纤丸和恩替卡韦联合治疗对乙型肝炎肝硬化代偿期患者肝纤维化和炎性因子的影响[J].新乡医学院学报,2019,36(4):319-322.
[9] 冯海群. 安络化纤丸联合恩替卡韦治疗代偿期乙肝肝硬化临床疗效[J].实用中医内科杂志,2021,35(9):63-65.
[10] 李小红. 评价中医通络消癥汤治疗乙肝肝硬化代偿期肝郁脾虚夹瘀证的临床疗效[J].药品评价,2020,17(1):28-29,33.
[11] 胡会芬,刘雯,谭林.富马酸替诺福韦联合扶正化瘀治疗对乙肝肝硬化患者肝纤维化程度及免疫状态的影响[J].河北医学,2021,27(4):686-692.
[12] 华远铎. 安络化纤丸联合恩替卡韦对乙型肝炎患者肝纤维化及肝功能的影响[J].河南医学研究,2020,29(24):4544-4546.
[13] 卢玮,高玉华,王珍子,等.安络化纤丸对肝纤维化大鼠转化生长因子β1及相应信号通路的影响[J].中华肝脏病杂志,2017,25(4):257-262.
[14] 周小惠. 恩替卡韦分散片联合安络化纤丸治疗乙肝肝硬化的临床疗效研究[J].世界复合医学,2020,6(8):180-182.
[15] 张楠. 舒肝冲剂联合安络化纤丸治疗肝硬化代偿期肝郁脾虚夹瘀证的临床效果分析[J].黑龙江医药科学,2021,44(1):197-198.
[16] 李朝晖,张晓龙,郭彦清,等.安络化纤丸联合恩替卡韦治疗乙肝肝硬化的效果及对肝功能的影响[J].中国医药导报,2020,17(28):151-154.